Biophytis, for which SATT Lutech ensured the transfer of technology between the IBPS (Institut de Biologie Paris Seine, Sorbonne University) and the start-up, has just obtained authorization from the French National Agency for Medicines and Health Products Safety to start the COVA clinical trial with Sarconeos (BIO101) in the potential treatment of acute respiratory failure associated with COVID-19. The company has already received clearance from the FDA (in the United States), the FAMHP (in Belgium) and the MHRA (in the United Kingdom).
The phase 2/3 clinical trial is due to start in the coming weeks in France, particularly at Pitié-Salpétrière. Stanislas Veillet, Chairman and CEO of Biophytis, declares: “This trial will start in France in particular at La Pitié-Salpétrière hospital, associated with the Faculty of Medicine of Sorbonne University, a long-standing partner of Biophytis. This authorization comes at a key time of the resurgence of the epidemic in France and in Europe, thus reminding us of the urgency of finding innovative treatments against this pandemic ".
Biophytis is a company specializing in the development of drug candidates for the treatment of age-related diseases, in particular neuromuscular diseases